Department of Radiotherapy, Policlinico Umberto I Sapienza University of Rome, Rome, Italy.
Biomed Res Int. 2013;2013:740195. doi: 10.1155/2013/740195. Epub 2013 Jul 10.
Our interest was to monitor treatment response using ADC value to predict response of rectal tumour to preoperative radiochemotherapy.
Twenty-two patients were treated with long course of radiochemotherapy, followed by surgery. Patients were examined by diffusion-weighted imaging MRI at three-time points (prior, during, and after radiochemotherapy) and were classified as responders and nonresponders.
A statistical significant correlation was found between preradiochemotherapy ADC values and during treatment ADC values, in responders (F = 21.50, P value <0.05). An increase in ADC value during treatment was predictive of at least a partial response.
Response of tumour to neoadjuvant therapy cannot be easily evaluated, and such capability might be of great importance in clinical practice, because the number of irradiated and operated patients may be superior to the number of who will really benefit from this multimodal treatment. A reliable prediction of the final clinical TN stage would allow radiotherapist to adapt multidisciplinary approach to a less invasive management, sparing surgical procedure in responder patients or even allowing an early surgery in nonresponders, which would significantly reduce radiochemotherapy related toxicity. Conclusion. Early evaluation of response during neoadjuvant radiochemotherapy treatment shows great promise to predict tumour response.
我们的兴趣是使用 ADC 值监测治疗反应,以预测直肠肿瘤对术前放化疗的反应。
22 名患者接受长程放化疗,然后进行手术。患者在三个时间点(治疗前、治疗期间和治疗后)接受扩散加权成像 MRI 检查,并分为反应者和非反应者。
在反应者中,治疗前 ADC 值与治疗期间 ADC 值之间存在统计学显著相关性(F = 21.50,P 值<0.05)。治疗期间 ADC 值的增加预测至少部分反应。
肿瘤对新辅助治疗的反应不易评估,这种能力在临床实践中可能非常重要,因为接受放疗和手术的患者数量可能超过真正受益于这种多模式治疗的患者数量。对最终临床 TN 分期的可靠预测将允许放疗师采用较少侵袭性的管理方法来适应多学科方法,在反应者中避免手术程序,甚至允许非反应者早期手术,这将显著降低放化疗相关毒性。结论。在新辅助放化疗治疗期间早期评估反应显示出很大的潜力,可以预测肿瘤反应。